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Abstract  
According to the Multiple Sclerosis International Federation, it is estimated that 2.5 million people worldwide 
suffer from Multiple Sclerosis (MS). MS aetiology is still uncertain, however its complex pathogenesis and 
unpredictable clinical course generates intense suffering and represents a continuous challenge for nurses to 
identify it. The aim of this article is to provide a review into the concept of Suffering in patients with MS, other 
than cancer patients. For people diagnosed with this disease suffering becomes a natural human response since 
symptoms tend to register unpredictable levels of variation in type, severity and progression, leading to an 
increasing degree of uncertainty. In the health-disease transition processes of people diagnosed with MS who are 
experiencing suffering, the palliative nursing interventions aimed at the relief of symptoms can increase hope 
and help people to adapt to future expectations and experience a better transition process. 




The demographic transition from a younger to an 
ageing population has significant socio-economic 
implications, impacting sustainability and social 
policies, as well as at a personal level with the 
adoption of new lifestyles, which contributes to a 
change in the epidemiological morbidity and 
mortality of  some diseases.  
Nowadays, chronic diseases are considered one 
of the greatest public health problems as they are 
long-lasting, almost always irreversible and 
always associated with long term disability. 
Consequently, they greatly affect the life of 
individuals (physical, emotional and socially), 
change family relationships and require 
continuous healthcare services.   
The chronic disease represents an obstacle or a 
constraint to personal interests and to the 
fulfilment of individual needs, thus the transition 
to this condition is often a source of suffering, 
frustration and adaptation problems (Meleis et al., 
2000).  
The concept of transition is central to nursing 
(Meleis et al., 2000; Meleis, 2007, 2010). Meleis 
et al. (2000, 2007, 2010) developed a middle 
range theory based on transition experiences 
triggered by life events. Transition is a process of 
change from one situation, condition or status to 
another. It means transformation and personal 
development. It requires adjustment and 
adaptation. Meleis (2010) argues that the main 
challenge of nursing interventions is to help 
p ople experience healthier transitions in order to 
achieve personal balance and well-being. 
According to this theory, MS patients experience 
health/disease transitions as a result of a 
pathological process, where the nurse is required 
to have in-depth understanding of the MS patient 
and the impact of the disease on patient and 
family. 
The different life stories (Margareth, 2010; 
Oliveira et al., 2012; Frank, 2015) are centred on 
the suffering as a phenomenon which manifests 
itself both inside and outside the context of the 
disease, in the form of a variety of experiences. 





Suffering may involve experiencing, going 
through, dealing with, anguish, sadness, loss 
and/or unpredictable and undesirable changes 
(Wright, 2005).The suffering is personal, deep 
and unrelated to age (Encarnacao et al., 2015). 
The individual who is suffering often raises 
questions, such as: why me? What did I do to 
deserve this? (Ferrell and Coyle, 2008); He 
desperately tries to obtain an explanation of the 
causes of the disease and thinks of how he will be 
able to cope with this condition (Encarnacao et 
al., 2015; Hemberg, 2017b). 
Multiple Sclerosis (MS) is an unpredictable, 
chronic disease of complex pathogenesis, which 
causes great suffering to people who suffer from 
this condition and their families (Wollin et al., 
2006; Russell, 2010; Golla et al., 2014; Strupp et 
al., 2016). It represents an enormous challenge 
for nurses (Golla et al., 2014; Harrison, 2014).  
Because of the nature of care, nurses establish a 
close relationship with the individual and their 
family, share their personal experiences and play 
an important role as witnesses of their suffering 
(Wright, 2005). Studies on MS provide nurses 
with a better understanding of the pathology and 
its related suffering (Kurtzke, 1983; Sadovnick, 
2001; Zorzon et al., 2001; Boeije, 2004; DeBolt 
and McCubbin, 2004; Wollin, 2006; Fry et al., 
2007; Russell, 2010; Feinstein, 2011; Straudi et 
al., 2013; Harrison, 2014; Alschuler, 2015), and 
empowers them to provide specialised 
interventions to relieve suffering of patients and 
families.  
The purpose of this article is to explore the 
concept of suffering in people with MS. We hope 
it encourages future research towards potential 
targeted interventions to soothe and relieve 
suffering in these people, beyond cancer patients. 
In fact, relief of suffering has been mainly 
associated to cancer patients and their families (at 
home or in palliative care units). However, there 
are still few scientific studies on the relief of 
suffering in patients with incurable, progressive, 
long-term diseases, such as MS (Elman et al., 
2007). 
About MS 
According to the Multiple Sclerosis International 
Federation (2017) it is estimated that 2.3 million 
people suffer from MS worldwide, making it the 
most common autoimmune disease of the 
nervous system. The European Multiple Sclerosis 
Platform (2017) further indicates that there are 
over 400,000 people with MS in Europe, with 
higher incidence in Nordic countries.  
This is a highly disabling disease (Kurtzke, 1983) 
with an important social dimension, since the age 
range for the diagnosis is in early adulthood, 
between 20 and 40 years old (Boeije and 
Janssens, 2004; DeBolt and McCubbin, 2004). 
The physical and mental impairment of the 
individual impacts their academic and 
professional life, leading to recurrent absences 
from work, thus seriously affecting the livelihood 
for themselves and their families.  
The aetiology of MS is multifactorial; however, 
evidence has shown that both genetic and 
environmental factors are likely to play a 
significant role in the onset of the disease 
(Compston and Coles, 2008). The National 
Multiple Sclerosis Society has defined four 
standard types of MS (Lublin et al., 2015): i) 
Relapsing-Remitting MS (RRMS), characterised 
by relapses that can last days or weeks, followed 
by periods of remission when symptoms improve 
or disappear; ii) Secondary-Progressive MS 
(SPMS), initially characterised by relapsing-
remitting periods and  later becomes progressive, 
with gradual loss of physical and cognitive 
functions which, in many cases, can be 
irreversible; iii) Primary-Progressive MS 
(PPMS), characterised by symptoms that tend to 
worsen from the onset with no remission of the 
initial relapse; and iv) Progressive-Relapsing MS 
(PRMS), characterised by being initially 
progressive, with clearly identifiable relapses, 
full or partial recovery and increasing severity of 
symptoms between relapses. There are other 
typical variants of MS and the discussion on 
whether these pathologies are variants of MS or 
autonomous diseases raises an important issue 
among experts (Stadelmann and Bruck, 2004). 
These forms of MS show the unpredictable 
prognosis of the disease, even among people with 
the same MS typology. The disease is thus an 
inevitable experience due to the severe 
discomfort caused by a perception of current or 
imminent threat to the individual’s integrity or 
life (Bjorkmark, & Koskinen, 2016).  This 
translates into suffering, according to Cassell 
(2004), Ferrell and Coyle (2008) and Krikorian et 
al. (2014). 
MS is caused by a demyelination of nerve fibres 
n the central nervous system (CNS). This 
clinical semiology can trigger the onset of a vast 





number of signs and symptoms, including 
fatigue, physical weakness, spasticity, ataxia, 
dysarthria, dysphagia, phosphine, diplopia, 
nystagmus, acute or chronic pain, bladder 
dysfunction, sexual dysfunction, and cognitive 
impairment, among others, which can be of 
short/long lasting or permanent (Klingbeil et al., 
2004; Compston and Coles, 2008). Advances in 
MS treatments have led to more effective 
interventions. Initially the same medication used 
to treat infections, rheumatic diseases, and cancer 
was also prescribed to MS patients. In addition to 
the typical therapy with corticosteroids, the 
current MS therapy involves a group of 
substances described as immunomodulatory (e.g., 
interferon α and β, fingolimode or glatiramer 
acetate) (Cohen et al., 2010; La Mantia et al., 
2015). These drugs may produce serious, adverse 
side effects and are ineffective in preventing 
disease progression in many MS patients (Racca 
et al., 2015; Chen and Ding, 2016). At an 
advance stage of the MS, the “risk of death from 
aspiration pneumonia, urinary tract infections, 
complications of falls and fractures, and sepsis 
secondary to pressure ulcers” (Solari et al., 2015, 
p. 185) is similar to cancer patients. 
Suffering as a human response of people with 
MS  
When exploring the concept of suffering, 
literature is consistent in relating sadness, fear, 
anguish, distress, loss; pain (chronic) and threat 
to the individual integrity as manifestations of 
suffering (Cassell, 2004; Wright, 2005; Ferrell 
and Coyle, 2008; Krikorian et al., 2014). The 
suffering experienced by people living in a 
health-disease transition process implies self-
awareness (perception, knowledge and 
understanding of the new health condition), 
commitment (self-involvement in relation to the 
disease) and changes that occur throughout life, 
as a result of events and critical points (Meleis et 
al., 2000), such as MS relapses. 
Physical symptoms compromise the quality of 
life (Kuempfel et al., 2007) of these people and 
can cause anguish and distress. Although pain 
tends to be associated with suffering, the two 
phenomenon are not synonymous (Cassell, 2004, 
2012; Encarnacao et al., 2015).  It would be very 
unrealistic to explain suffering solely as physical 
pain and thus underestimate the meaning and 
understanding of suffering, which  affects the 
intrinsic nature of the person and  their 
personhood (Ferrell and Coyle, 2008; Cassell, 
2012; Krikorian et al., 2014). Hence, when 
interpreting suffering, the approach must explore 
the individual thoroughly (e.g., physical, 
psychological, socially and so forth), as a whole 
(Cassell, 2012). Therefore, suffering in MS  is 
associated with physical symptoms, the prospect 
of job loss, the fear of not being able to pay for 
treatment (medications, travel from the 
residence-hospital-residence) due to insufficient 
socioeconomic resources, the fear of having to 
r ly on people or technical aids or becoming 
disabled (Bjorkmark, & Koskinen, 2016). All of 
these may trigger negative feelings (e.g., anger, 
pessimism, despair, revolt, distress) from the 
moment patients are confronted with the disease 
diagnosis, which is aggravated by the uncertainty 
of its prognosis. 
The disease shows higher prevalence in females 
causing additional concern to women when 
considering pregnancy and the impact that 
treatments may have in the development of the 
foetus (Sadovnick, 2001). Decision-making on 
health, changes in lifestyle, as well as treatment 
preparedness could be easier if the MS prognosis 
were predictable. However, people with MS are 
faced with high levels of uncertainty because the 
disease shows increasing changes in type, 
severity and progression in symptoms, which, 
according to Alschuler and Meghan (2015), have 
negative impact on patients’ psychological well-
being. Uncertainty can generate fear, anguish, 
and sadness that might influence decision-making 
on treatment preparedness, on motherhood, in 
finding a new job or in buying a house, and this 
suffering is very likely to undermine hope and 
future expectations. 
Suffering can cause depression (Patten at al., 
2017) that can arise from the fear and frustration 
of progressive disability and unpredictability of 
the course of the disease. On the other hand, 
depression may be from an organic source and be 
related to a possible disconnection at cortical or 
subcortical levels in the areas of projection of the 
limbic system (Zorzon et al., 2001). Thus, 
depression with organic origin, if not carefully 
monitored from the onset, is also likely to cause 
suffering. Studies show that suicidal tendencies 
are present in more than a quarter of the people 
diagnosed with MS, with an increased risk in 
young men who are at least five years into their 
diagnosis, and is related to the persistence and 
severity of depression, social isolation and 
alcohol abuse (Feinstein, 2011). 





Recent research studies highlight the fact the 
health professionals have the ethical 
responsibility to diagnose suffering in people 
with chronic diseases other that cancer, in order 
to provide specific care or even palliative care 
(Etkind et al., 2017).  
Palliative care (PC) has been focused almost 
entirely on cancer patients (Edmonds et al., 
2010), due to the unpredictable disease 
progression, usually associated with intense 
suffering and inevitable death. Thus, suffering 
relief becomes a major concern for these patients 
and their families. Today, symptoms related to 
cancer patients are comparable to the severity of 
symptoms at an advanced stage of some chronic 
disease, namely those suffering from advanced 
MS (Higginson et al., 2006). Therefore, 
according to this related severity of symptoms, 
palliative care may be considered as an effective 
response (Elman et al., 2007; Edmonds et al., 
2010; Opara et al., 2016). This specific care 
intervention aims to prevent, decrease or relieve 
suffering caused by the disease and potentially 
improve patients and families’ quality of life. 
Nursing focus: relief of Suffering in MS  
Among the team of health professionals, nurses 
have a closer and longer interaction with 
suffering related to people with MS. The nurses 
are the main caregivers of people suffering from 
chronic diseases and are often their sole support 
(Van Der Cingel, 2009). For nurses, it is essential 
to know the meaning and manifestations of 
suffering in MS patients experiencing a health-
disease transition process (Leary et al., 2015). 
This knowledge enables the improvement of the 
quality of the relationship between the nurse, 
patients and families and the understanding of 
their deepest feelings, thoughts and behaviours. It 
also encourages people with MS to acknowledge 
events and critical situations arising from 
personal experience, helping them to accept these 
episodes, enabling coping, mobilization and self-
resilience to face the disease (Antonovsky, 1988; 
Hemberg, 2017a), revealing their strengths 
(Gottlieb, 2013; Hemberg, Eriksson, & Nystrom, 
2016) and encouraging them to perceive the 
experience of suffering as an opportunity to 
acquire knowledge, thus avoiding the feeling of 
loss of control and helplessness towards suffering 
(Hemberg, 2017a). 
In order to identify the suffering in the person 
with MS, specific assessment instruments are 
r quired (Krikorian et al., 2013), such as 
interview (Cassell, 2004; Charon, 2004, 2007). 
The patient interview must contain objective and 
specific questions addressing this phenomenon 
giving nurses the necessary information for an 
efficient intervention aiming at reducing or 
eliminating suffering. 
The interventions of the nurses should be 
structured on a partnership logic, including the 
patients – and their informal caretakers – in the 
planning and provision of the medical care that is 
destined to them. That means that professionals 
and patients are on an equality relationship on the 
decision making process. This approach 
a knowledges and respects the experiences and 
knowledges from both partners. This does not 
mean that the nurse will transfer all responsibility 
to the person. This means that the nurse listens to 
the person, acknowledges the experience of the 
person and together they elaborate a care plan 
which is tailored to the objectives, needs, 
preferences, lifestyles and circumstances of the 
person and the family. 
Some therapeutic education programs have been 
developed with the goal of reducing the impact of 
the suffering of the disease (Baixinho et al., 
2016; Rodrigues and Moreira, 2015), with 
structured and organized activities adapted to the 
needs of each patient. For nine weeks Rodrigues 
and Moreira (2015) implemented a therapeutic 
education program, which had the goal of 
increasing the knowledge of the patients about 
the EM, improving the symptomology; 
improving the management of complications, 
improving the knowledge and the management of 
the treatment; to promote the active role of the 
patient, to develop a critic spirit and decision 
making skills. After the evaluation of the 
implementation of the program, the authors 
determined that the therapeutic education allows 
for the patient with EM to rebuild his life journey 
through the acquisition of newfound knowledge. 
It also allows to mobilize his internal and 
external resources, to develop new skills and to 
acquire a new meaning for life, reducing the 
impact that the disease has on him (Bjorkmark, & 
Koskinen, 2016). Rodrigues and Moreira (2015) 
acknowledge that the nurses involved in the 
training, have improved their relationship, 
communicational and teaching skills. In addition, 
nursing education should also include simulated 
training (e.g., roleplay, PBL- Problem Based 
Learning), fostering the necessary skills that will





enable future nurses to meet the specific needs of 
those who suffer (Ferrell and Coyle, 2008; 
Maykut, & Porter, 2015). 
Conclusion 
Multiple Sclerosis is a chronic inflammatory 
disease affecting the central nervous system with 
a highly variable clinical course, depending on 
the type, severity and progression of symptoms, 
which contributes to increasing levels of 
uncertainty as to its prognosis. It affects mainly 
adults in their twenties and forties with higher 
incidence in women. It is a potentially disabling 
disease, which causes aggravated suffering. 
In the health-disease transition processes 
experienced by people diagnosed with MS and 
their families, suffering is expected. Loss of 
hope, helplessness, anger, anguish, despair, 
pessimism and financial difficulties, all derive 
from the medical treatments and potential 
shortfalls that the person may endure; and 
threaten their future expectations by increasing 
the levels of uncertainty which could lead to 
depression, contributing to the risk of suicide. 
In the health team, nurses are caregivers working 
in close relationship with patients and families. 
They actively intervene in patients’ personal 
experiences, and play an important role as 
witnesses of their suffering.  At an advance stage 
of the disease, palliative care can be an effective 
response to relieve suffering of MS patients. 
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